AZD1386
Phase 2Small molecule
AstraZenecaAZD1386 is one of 106 small molecule programs targeting Neuropathic Pain. It is currently in Phase 2.
3
Indications
11
Total Trials
0
Active Trials
105
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
778 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsPreclinical
Toradol
RochePreclinical
AZD1386
AstraZenecaPhase 2
Voltaren
CCerimon Pharmaceuticals
Preclinical
Cataflam
NovartisPreclinical
Paracetamol
GSKPreclinical
Chirocaine
PPurdue Pharma LP
Preclinical
Lunesta
Akero TherapeuticsPreclinical
Botox
AbbViePreclinical
Lornoxicam
PPOZEN
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Double-blind1 trial
Gastroesophageal Reflux Disease1 trial
5 more indications
Excretion1 trial
Neuropathic Pain1 trial
Osteoarthritis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AZD1386. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company